000283043 001__ 283043
000283043 005__ 20251230103619.0
000283043 0247_ $$2doi$$a10.1002/alz70855_107337
000283043 0247_ $$2ISSN$$a1552-5260
000283043 0247_ $$2ISSN$$a1552-5279
000283043 037__ $$aDZNE-2025-01450
000283043 041__ $$aEnglish
000283043 082__ $$a610
000283043 1001_ $$0P:(DE-2719)2000005$$aDüzel, Emrah$$b0$$eFirst author
000283043 1112_ $$aAlzheimer’s Association International Conference$$cToronto$$d2025-07-27 - 2025-07-31$$gAAIC 25$$wCanada
000283043 245__ $$aAmygdala Novelty Responses, Depressive Symptoms, and Tau Pathology in Preclinical Alzheimer's Disease: An fMRI Investigation
000283043 260__ $$c2025
000283043 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1767014471_31204
000283043 3367_ $$033$$2EndNote$$aConference Paper
000283043 3367_ $$2BibTeX$$aINPROCEEDINGS
000283043 3367_ $$2DRIVER$$aconferenceObject
000283043 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$mjournal
000283043 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000283043 3367_ $$2ORCID$$aOTHER
000283043 520__ $$aBackground: Late-life depression (LLD) is a well-established risk factor for Alzheimer's disease (AD) and has been linked to cognitive decline. The amygdala, an important region for emotional regulation and novelty detection, is one of the earliest sites of tau accumulation in AD. However, it remains unclear how depressive symptoms and tau burden interact with amygdala function in preclinical AD stages. This study examines the relationship between amygdala novelty responses, depressive symptoms.Method:A total of 190 participants (HC = 58, SCD = 88, MCI = 44) underwent functional MRI (fMRI) to assess amygdala novelty responses. Depression severity was measured using the GDS, and tau pathology was classified based on CSF phosphorylated tau (p-Tau) and total tau (t-Tau) levels. Participants were further categorized based on depressive symptoms (GDS = 0 vs. GDS ≥1) and tau status (Tau (-) vs. Tau (+)) for statistical analyses.Result:Group comparisons revealed significantly higher GDS scores in SCD and MCI groups compared to HC (p < 0.05), reflecting increased depressive symptoms in individuals with cognitive complaints. However, no significant correlation was observed between amygdala novelty responses and GDS scores across diagnostic groups. Additionally, CSF tau levels (p-Tau and t-Tau) did not significantly interact with depressive symptoms in predicting amygdala responses. The lack of significant findings in amygdala response may be attributed to the relatively low overall severity of depressive symptoms in the sample, which could limit detectability of neural alterations.Conclusion: Although prior studies have indicated that late-life depression and tau pathology are associated with the progression of Alzheimer's disease (AD), our findings suggest that subclinical depressive symptoms do not significantly impact amygdala novelty responses in preclinical AD. The observed increase in depressive symptoms in SCD and MCI groups suggests that affective changes may still be an important factor in disease progression, but their relationship with amygdala function remains unclear. Future research should explore clinically significant depression, longitudinal changes in affective symptoms, and other neurobiological mechanisms, such as amyloid burden and neuroinflammation, to better understand the early neural changes associated with AD.
000283043 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000283043 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x1
000283043 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000283043 650_7 $$2NLM Chemicals$$atau Proteins
000283043 650_2 $$2MeSH$$aHumans
000283043 650_2 $$2MeSH$$aMale
000283043 650_2 $$2MeSH$$aFemale
000283043 650_2 $$2MeSH$$aAmygdala: physiopathology
000283043 650_2 $$2MeSH$$aAmygdala: diagnostic imaging
000283043 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000283043 650_2 $$2MeSH$$atau Proteins: cerebrospinal fluid
000283043 650_2 $$2MeSH$$aAged
000283043 650_2 $$2MeSH$$aDepression: physiopathology
000283043 650_2 $$2MeSH$$aCognitive Dysfunction: physiopathology
000283043 650_2 $$2MeSH$$aCognitive Dysfunction: diagnostic imaging
000283043 650_2 $$2MeSH$$aAlzheimer Disease
000283043 650_2 $$2MeSH$$aMiddle Aged
000283043 7001_ $$0P:(DE-2719)9002417$$aCikrikcili, Ugur$$b1
000283043 7001_ $$0P:(DE-2719)2814326$$aSchott, Björn H.$$b2
000283043 7001_ $$0P:(DE-HGF)0$$aJockschat, Thomas Nickl$$b3
000283043 7001_ $$0P:(DE-2719)2812972$$aBerron, David$$b4
000283043 7001_ $$0P:(DE-2719)9000770$$aSoch, Joram$$b5
000283043 7001_ $$0P:(DE-2719)9001743$$aKrohn, Friedrich$$b6$$eLast author
000283043 773__ $$0PERI:(DE-600)2201940-6$$a10.1002/alz70855_107337$$gVol. 21, no. S1, p. e107337$$nS1$$pe107337$$tAlzheimer's and dementia$$v21$$x1552-5260$$y2025
000283043 8564_ $$uhttps://pub.dzne.de/record/283043/files/DZNE-2025-1450.pdf$$yOpenAccess
000283043 8564_ $$uhttps://pub.dzne.de/record/283043/files/DZNE-2025-1450.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000283043 909CO $$ooai:pub.dzne.de:283043$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000283043 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000005$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000283043 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002417$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000283043 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814326$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000283043 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2812972$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000283043 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000770$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000283043 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001743$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000283043 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000283043 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x1
000283043 9141_ $$y2025
000283043 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000283043 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000283043 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000283043 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283043 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-01-06$$wger
000283043 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000283043 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bALZHEIMERS DEMENT : 2022$$d2025-01-06
000283043 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000283043 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000283043 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000283043 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-01-06
000283043 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000283043 9201_ $$0I:(DE-2719)5000006$$kAG Düzel$$lClinical Neurophysiology and Memory$$x0
000283043 9201_ $$0I:(DE-2719)1410002$$kAG Fischer$$lEpigenetics and Systems Medicine in Neurodegenerative Diseases$$x1
000283043 9201_ $$0I:(DE-2719)5000070$$kAG Berron$$lClinical Cognitive Neuroscience$$x2
000283043 9201_ $$0I:(DE-2719)1440015$$kClinical Dementia Research (Göttingen)$$lClinical Dementia Research (Göttingen)$$x3
000283043 980__ $$aabstract
000283043 980__ $$aVDB
000283043 980__ $$aUNRESTRICTED
000283043 980__ $$ajournal
000283043 980__ $$aI:(DE-2719)5000006
000283043 980__ $$aI:(DE-2719)1410002
000283043 980__ $$aI:(DE-2719)5000070
000283043 980__ $$aI:(DE-2719)1440015
000283043 9801_ $$aFullTexts